Healthcare Jul 20, 2021 05:26 PM (GMT+8) · EqualOcean
On July 20, British silicon intelligence and JinFang medicine announced that they had reached a strategic cooperation agreement. The two sides will promote and accelerate the research and development of innovative drugs for new targets and difficult drug targets in the fields of tumor and immune diseases. According to the agreement, the two sides will combine the "global new" drug R & D system of JinFang pharmaceutical and the end-to-end artificial intelligence drug R & D platform of BSI to explore the dynamic structure-activity relationship between the target protein and drug molecules through precise research, accelerate the screening and design of new highly selective inhibitors And a new generation of targeted drugs is expected to crack the mechanism of drug resistance.

This text is a result of machine translation.